Caribou Biosciences (CRBU) Stock Price, News & Analysis

Company Overview

Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma. The company also develops CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma; and CB-012, an allogeneic anti-CD371 CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.

Key Stats

• Today's Range: $1.82 to $1.97
• 50-Day Range: $1.12 to $2.48
• 52-Week Range: $0.66 to $3.00
• Volume: 1.40 million shs
• Average Volume: 1.27 million shs
• Market Capitalization: $172.27 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $6.67
• Consensus Rating: Buy

Caribou Biosciences Stock Analysis - MarketRank™

Caribou Biosciences scored higher than 58% of companies evaluated by MarketBeat, and ranked 474th out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Caribou Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Caribou Biosciences has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Caribou Biosciences are expected to decrease in the coming year, from ($1.64) to ($1.78) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Caribou Biosciences is -1.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Caribou Biosciences is -1.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Caribou Biosciences has a P/B Ratio of 1.04. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

4.82% of the float of Caribou Biosciences has been sold short.

Short Interest Ratio / Days to Cover

Caribou Biosciences has a short interest ratio ("days to cover") of 2.5, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Caribou Biosciences has recently decreased by 15.58%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Caribou Biosciences does not currently pay a dividend.

Dividend Growth

Caribou Biosciences does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

4.82% of the float of Caribou Biosciences has been sold short.

Short Interest Ratio / Days to Cover

Caribou Biosciences has a short interest ratio ("days to cover") of 2.5, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Caribou Biosciences has recently decreased by 15.58%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.0 / 5
• News Sentiment: 0.58

News Sentiment

Caribou Biosciences has a news sentiment score of 0.58. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 11 news articles for Caribou Biosciences this week, compared to 6 articles on an average week.

Search Interest

Only 5 people have searched for CRBU on MarketBeat in the last 30 days. This is a decrease of -17% compared to the previous 30 days.

MarketBeat Follows

Only 2 people have added Caribou Biosciences to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Caribou Biosciences insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 8.28% of the stock of Caribou Biosciences is held by insiders.

Percentage Held by Institutions

77.51% of the stock of Caribou Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

CRBU Stock Analysis - Frequently Asked Questions

How have CRBU shares performed this year?

Caribou Biosciences' stock was trading at $1.59 on January 1st, 2025. Since then, CRBU shares have increased by 16.4% and is now trading at $1.85.

How were Caribou Biosciences' earnings last quarter?

Caribou Biosciences, Inc. (NASDAQ:CRBU) released its quarterly earnings data on Tuesday, August, 12th. The company reported ($0.35) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.40) by $0.05. The company earned $2.67 million during the quarter, compared to analysts' expectations of $1.64 million. Caribou Biosciences had a negative trailing twelve-month return on equity of 62.35% and a negative net margin of 1,800.93%.

When did Caribou Biosciences IPO?

Caribou Biosciences (CRBU) raised $202 million in an IPO on Friday, July 23rd 2021. The company issued 13,500,000 shares at $14.00-$16.00 per share.

Who are Caribou Biosciences' major shareholders?

Top institutional investors of Caribou Biosciences include Geode Capital Management LLC (1.05%), Aberdeen Group plc (0.97%), Bank of America Corp DE (0.87%) and Pale Fire Capital SE (0.83%). Insiders that own company stock include Rachel E Haurwitz, Barbara G Mcclung, Steven Kanner, Ryan Fischesser, Syed Ali-Aamir Rizvi and Sriram Ryali.
View institutional ownership trends.

How do I buy shares of Caribou Biosciences?

Shares of CRBU stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Caribou Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Caribou Biosciences investors own include Voyager Therapeutics (VYGR), American Water Works (AWK), The RMR Group (RMR), Waste Connections (WCN), AU Optronics (AUOTY), DiamondRock Hospitality (DRH) and iShares Micro-Cap ETF (IWC).

Company Calendar

• Last Earnings: 8/12/2025
• Today: 8/23/2025
• Next Earnings (Estimated): 11/05/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:CRBU
• CIK: 1619856
• Web: cariboubio.com
• Phone: 510-982-6030
• Fax: N/A
• Employees: 100
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Caribou Biosciences: $6.67
• High Price Target: $11.00
• Low Price Target: $3.00
• Potential Upside/Downside: +260.4%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.78)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$149.10 million
• Net Margins: -1,800.93%
• Pretax Margin: -1,801.03%
• Return on Equity: -62.35%
• Return on Assets: -49.65%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 6.66
• Quick Ratio: 6.66

Sales & Book Value

• Annual Sales: $9.99 million
• Price / Sales: 17.24
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.78 per share
• Price / Book: 1.04

Miscellaneous

• Outstanding Shares: 93,120,000
• Free Float: 85,412,000
• Market Cap: $172.27 million
• Optionable: Optionable
• Beta: 2.55